Brief: Else Successfully Completes Second Preclinical Study On The Path For FDA Approval Of World's First Whole Plant, Soy-Free Infant Formula
31/05/2022 12:53
May 31 (Reuters) - Else Nutrition Holdings Inc BABY.TO :
* ELSE SUCCESSFULLY COMPLETES SECOND PRECLINICAL STUDY ON
THE PATH
FOR FDA APPROVAL OF WORLD'S FIRST WHOLE PLANT, SOY-FREE INFANT
FORMULA
Source text for Eikon: ID:nGNXbJkRKX
Further company coverage: BABY.TO
Recent news on Else Nutrition Holdings
See all newsBrief: Else Nutrition Pursuing Parallel Listing On Canadian Securities Exchange To Ensure Market Continuity
Canada's Else Nutrition Q1 revenue falls on supply issues
Brief: Else Nutrition Expected to Benefit from FDA Regulatory Progress on Infant Formula Protein Standards
Brief: Else Nutrition Announces Appointment Of Natie Zilberberg As Chief Financial Officer
Brief: Else Nutrition Achieves Transformative Operational and Financial Progress in 2025